NanoVibronix, Inc. (NAOV) - Dilution Analysis

S-3 filing: This prospectus relates to the resale by the selling stockholder of up to 6,000,768 shares of common stock issuable upon the conversion of Series H Convertible Preferred Stock.

10-Q filing | 6.1M shares outstanding

10-K filing | 3.7M shares outstanding

10-Q filing | 1.1M shares outstanding

S-3/A filing: This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to 6,369,955 shares of our common stock.

8-K filing: NanoVibronix, Inc. sold 74,114 shares of common stock and prefunded warrants to purchase up to 217,090 shares in a registered direct offering, with net proceeds of approximately $1.8 million.

S-3 filing: This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to 1,347,935 shares of our common stock.

10-Q filing | 0.8M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 2,584,835 → 796,887

8-K filing: NanoVibronix, Inc. entered into a Securities Purchase Agreement to sell Series H Convertible Preferred Stock and warrants, with an initial closing on July 22, 2025, resulting in gross proceeds of $8 million. ($8.0M proceeds)

10-Q filing | 2.6M shares outstanding

8-K filing: NanoVibronix, Inc. completed a public offering on May 16, 2025, issuing 400,000 shares of Series G Convertible Preferred Stock and warrants to purchase up to 4,901,982 shares of Common Stock, with gross proceeds of approximately $10 million. ($10.0M proceeds)

S-1/A filing: This is a firm commitment public offering of Series G Convertible Preferred Stock and warrants to purchase common stock, along with common stock issuable upon conversion or exercise of the warrants.

S-1/A filing: This S-1/A filing relates to a firm commitment public offering of Series G Convertible Preferred Stock and warrants to purchase common stock.

S-1/A filing: This is a firm commitment public offering of Series G Convertible Preferred Stock and warrants to purchase common stock. The filing also relates to the shares of common stock issuable from time to time upon the conversion of the Preferred Stock, payment of dividends accrued on the Preferred Stock in shares of common stock upon conversion of the Preferred Stock, and the shares of common stock issuable upon exercise of the Warrants.

S-1/A filing: NanoVibronix, Inc. is offering Series G Convertible Preferred Stock and warrants to purchase common stock, with Dawson James Securities, Inc. acting as placement agent.

10-K filing | 0.8M shares outstanding

8-K filing: Stock split 1-for-11 | Outstanding: 8,716,327 → 792,394

8-K filing: Nanovibronix, Inc. consummated a merger with ENvue Medical Holdings, Corp. on February 14, 2025, issuing 1,734,995 shares of common stock and 57,720 shares of Series X Non-Voting Convertible Preferred Stock to ENvue's holders.

S-1 filing: NanoVibronix, Inc. is offering Series G Convertible Preferred Stock and warrants to purchase common stock.

8-K filing: NanoVibronix, Inc. issued 456,478 shares of common stock, a warrant to purchase up to 1,744,186 shares of common stock, and a pre-funded warrant to purchase up to 1,959,447 shares of common stock in exchange for a Series A-1 warrant to purchase up to 2,906,977 shares of common stock.

10-Q filing | 3.8M shares outstanding

10-Q filing | 2.8M shares outstanding

10-Q filing | 2.5M shares outstanding

10-K filing | 2.8M shares outstanding

10-Q filing | 2.0M shares outstanding

RW filing: The Registration Statement was never declared effective and no securities of the Company were sold in connection with the offering, so the withdrawal of the Registration Statement is consistent with the public interest and protection of investors.

S-3 filing: This S-3 filing registers the resale of up to 8,956,955 shares of common stock by selling stockholders.

8-K filing: NanoVibronix, Inc. entered into a securities purchase agreement for a private placement involving the issuance and sale of common shares, pre-funded warrants, and warrants, with net proceeds expected to be approximately $4.3 million.

10-Q filing | 1.7M shares outstanding

S-1/A filing: NanoVibronix, Inc. is offering shares of common stock, together with warrants to purchase shares of common stock, and prefunded warrants to purchase shares of common stock.

S-3 filing: NanoVibronix, Inc. may offer and sell from time to time, in one or more series or issuances and on terms that we will determine at the time of the offering, any combination of common stock, preferred stock, warrants and/or units up to an aggregate amount of $50,000,000.

S-1 filing: NanoVibronix, Inc. is offering shares of common stock, warrants, and prefunded warrants. The offering will terminate on a future date.

10-Q filing | 1.7M shares outstanding

10-K filing | 1.7M shares outstanding

8-K filing: Stock split 1-for-20 | Outstanding: 27,997,793 → 1,644,718

8-K filing: NanoVibronix, Inc. entered into a securities purchase agreement to sell 4,800,000 shares of common stock at $0.50 per share in a registered direct offering, expected to close on or about December 1, 2022. ($2.4M proceeds)

10-Q filing | 28.0M shares outstanding

10-Q filing | 28.0M shares outstanding

10-Q filing | 28.0M shares outstanding

10-K filing | 28.0M shares outstanding

10-Q filing | 27.9M shares outstanding

10-Q filing | 24.1M shares outstanding

10-Q filing | 21.2M shares outstanding

10-K filing | 4.2M shares outstanding

8-K filing: NanoVibronix, Inc. entered into letter agreements with existing accredited investors to exercise warrants to purchase up to 1,205,967 shares of common stock at $1.165 per share, with gross proceeds expected to be approximately $1.4 million. ($1.4M proceeds)

S-3 filing: Resale of common stock by selling stockholders.

8-K filing: NanoVibronix, Inc. completed a private placement issuing 5,914,285 shares of common stock and pre-funded warrants to purchase up to 2,657,144 shares for gross proceeds of approximately $6.0 million. ($6.0M proceeds)

10-Q filing | 4.2M shares outstanding

8-K filing: NanoVibronix, Inc. entered into an underwriting agreement with H.C. Wainwright & Co., LLC to sell 1,794,783 shares of common stock at $1.00 per share, with Wainwright having a 30-day option to purchase up to an additional 269,217 shares. ($1.79M proceeds)

8-K filing: NanoVibronix, Inc. completed an upsized firm commitment offering of 4,531,434 shares of common stock at $0.75 per share, resulting in net proceeds of approximately $2.7 million, and issued warrants to Wainwright to purchase 339,858 shares of Common Stock. ($3.4M proceeds)

8-K filing: On August 5, 2020, the Company issued an additional 375,000 shares of common stock to Bespoke Growth Partners, Inc. under a consulting agreement.

S-3 filing: NanoVibronix, Inc. may offer and sell from time to time, in one or more series or issuances, any combination of common stock and preferred stock up to an aggregate amount of $50,000,000.

10-Q filing | 4.3M shares outstanding

8-K filing: NanoVibronix, Inc. issued a promissory note for $200,000 and a warrant to purchase 100,000 shares of common stock to an accredited investor.

10-K filing | 4.3M shares outstanding

S-3 filing: The filing relates to the registration of resale of common stock and common stock warrants issued under several stock purchase agreements.